RxDoctor Payments Data

Maxim Bitunov, MD

Internal Medicine · Pittsfield, MANPI 1821430349

Payments from drug & device makers

$2,813in general payments, 2019–2025

Across 48 payments — averaging $58.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$520
  • AbbVie$407
  • GSK$302
  • AstraZeneca$190
  • Johnson & Johnson$184
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$160
  • plus $1K from 10 others

What the payments were for

  • Food & beverage$2,813100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,813 in reported general payments places this provider in the 85th percentile of 4,983 internal medicine providers in Massachusetts.

See all internal medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$283,337
Medicare patients
636
Services billed
3,231

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban122$115,464
TrulicityDulaglutide71$86,953
MounjaroTirzepatide53$64,331
RybelsusSemaglutide38$57,549
XareltoRivaroxaban38$52,457
JardianceEmpagliflozin28$45,274
Trelegy ElliptaFluticasone/Umeclidin/Vilanter54$40,440
FarxigaDapagliflozin Propanediol41$39,503
OzempicSemaglutide38$38,684
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr46$20,110
JanuviaSitagliptin Phosphate15$19,938
Repatha SureclickEvolocumab16$15,261
Breo ElliptaFluticasone/Vilanterol27$11,340
Incruse ElliptaUmeclidinium Bromide25$10,559
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog20$8,372

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$520$151,284124 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta$302$82,450152 claims
Johnson & JohnsonXarelto$184$52,45738 claims
Boehringer IngelheimJardiance$125$45,27428 claims
AstraZenecaFarxiga, Bevespi Aerosphere$190$45,15153 claims
AbbVieSynthroid$407$2,23424 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,983 internal medicine providers in Massachusetts.

Other internal medicine in Pittsfield

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →